GnRH Agonist as Luteal Support in FET Cycles

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Back ground: A single dose of GnRH analogue in the luteal phase is reported to improve the outcome of IVF/ICSI treatments but the effect in FET cycles has not been reported.

Aim: To compare the results of frozen thawed embryo transfers with and without GnRHa analogue support Primary end point: IR, PR, on going PR Secondary end point: hCH, E2 and progesterone levels 14 days after thawing

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Turku University Hospital
• Treatments: Hormones; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• 20 - 45 year old women comig to frozen thawed embryo transfer

Exclusion Criteria:

• The age of the woman over 42 years during the initial ICF/ICSI- treatment from which the embryos derive

• Abnormal uterus

• Known abnormality of karyotype of the woman or her partner

• Severe male factor as an exclusive reason for subfertility

• Allegy for triptorelin acetate